Previous 10 | Next 10 |
home / stock / cytk / cytk articles
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition prop...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 80 points on Wednesday. The Dow traded up 0.22% to 37,626...
Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with s...
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced five presentations at th...
Cytokinetics Inc (NASDAQ: CYTK), a late-stage biotech company focused on cardiovascular treatments, is reportedly exploring potential takeover...
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Gainers Applied UV, Inc. (NASDAQ: AUVI) gained 60.4% to $0.4924. Applied UV said its new product, the Airocide® Pro+ air purification system f...
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's s...
News, Short Squeeze, Breakout and More Instantly...
Cytokinetics Incorporated Company Name:
CYTK Stock Symbol:
NASDAQ Market:
Cytokinetics Incorporated Website:
2024-06-20 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian parti...
2024-06-04 10:30:05 ET B. Riley analyst issues BUY recommendation for CYTK on June 4, 2024 08:58AM ET. The previous analyst recommendation was Buy. CYTK was trading at $49.018 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...